NCT02860559 is a Phase 1 clinical trial of TBX-1400 in Severe Combined Immunodeficiency, sponsored by Taiga Biotechnologies, Inc..

Who is sponsoring NCT02860559?

NCT02860559 is sponsored by Taiga Biotechnologies, Inc..

What drugs are being tested in NCT02860559?

Interventions in NCT02860559: TBX-1400.

What condition does NCT02860559 study?

NCT02860559 studies Severe Combined Immunodeficiency.

Is NCT02860559 still recruiting?

NCT02860559 is currently status unknown. Last updated 6 October 2020.

Last reviewed 2020-10-06 · How we verify

NCT02860559

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

Status unknown Phase 1 Last updated 6 October 2020

What this trial tests

Phase 1 trial testing TBX-1400 in Severe Combined Immunodeficiency in 8 participants. Status unknown.

Timeline

1 August 2021

Primary endpoint
1 February 2024

1 March 2024

Quick facts

Lead sponsor	Taiga Biotechnologies, Inc.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 August 2021
Primary completion	1 February 2024
Estimated completion	1 March 2024
Sites	2 locations across Israel

Drugs / interventions tested

TBX-1400 — full drug profile →

Conditions studied

Severe Combined Immunodeficiency — all drugs for Severe Combined Immunodeficiency →

Sponsor

Taiga Biotechnologies, Inc. — full company profile →

Who can join

Adults 1 Month to 4, any sex, with Severe Combined Immunodeficiency. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adverse Events following transplant with TBX-1400
Time frame: Two years
Adverse events from subject or parent reporting or other assessments

Sponsor's own description

This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second goal is to find out what effects TBX-1400 stem cells have on time to engraftment in pediatric subjects with SCID. The study hypothesis is that TBX-1400 cells will shorten the time to immune reconstitution after transplant.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.
Yanir A, Schulz A, Lawitschka A, Nierkens S, et al · · 2021 · cited 35× · PMID 35087775 · DOI 10.3389/fped.2021.786017

Verify or expand the search:

Other recruiting trials for Severe Combined Immunodeficiency

Currently open trials in the same condition.

NCT05651113 — The Experience of Screening for SCID · recruiting
NCT03597594 — Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Comb · Phase 1, PHASE2 · active not recruiting
NCT00055172 — Genetic Basis of Immunodeficiency · recruiting

Other Taiga Biotechnologies, Inc. trials

Trials by the same sponsor.

NCT04709458 — Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02860559 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taiga Biotechnologies, Inc.
Last refreshed: 6 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02860559.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing